3-[(4R)-1,3-oxazolidin-4-yl]-1-[3-[4-[5-(trifluoromethyl)pyrazin-2-yl]oxyphenyl]azetidin-1-yl]propan-1-one
C20H21F3N4O3 — CID 175711335
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[(4R)-1,3-oxazolidin-4-yl]-1-[3-[4-[5-(trifluoromethyl)pyrazin-2-yl]oxyphenyl]azetidin-1-yl]propan-1-one
3-[(4R)-1,3-oxazolidin-4-yl]-1-[3-[4-[5-(trifluoromethyl)pyrazin-2-yl]oxyphenyl]azetidin-1-yl]propan-1-one (PubChem CID 175711335) has the molecular formula C20H21F3N4O3 and a molecular weight of 422.41 g/mol. Its IUPAC name is 3-[(4R)-1,3-oxazolidin-4-yl]-1-[3-[4-[5-(trifluoromethyl)pyrazin-2-yl]oxyphenyl]azetidin-1-yl]propan-1-one.
Molecular Properties
| Compound Name | 3-[(4R)-1,3-oxazolidin-4-yl]-1-[3-[4-[5-(trifluoromethyl)pyrazin-2-yl]oxyphenyl]azetidin-1-yl]propan-1-one |
|---|---|
| PubChem CID | 175711335 |
| Molecular Formula | C20H21F3N4O3 |
| Molecular Weight | 422.41 g/mol |
| Exact Mass | 422.16 |
| IUPAC Name | 3-[(4R)-1,3-oxazolidin-4-yl]-1-[3-[4-[5-(trifluoromethyl)pyrazin-2-yl]oxyphenyl]azetidin-1-yl]propan-1-one |
| SMILES | O=C(CC[C@@H]1COCN1)N1CC(c2ccc(Oc3cnc(C(F)(F)F)cn3)cc2)C1 |
| InChI | InChI=1S/C20H21F3N4O3/c21-20(22,23)17-7-25-18(8-24-17)30-16-4-1-13(2-5-16)14-9-27(10-14)19(28)6-3-15-11-29-12-26-15/h1-2,4-5,7-8,14-15,26H,3,6,9-12H2/t15-/m1/s1 |
| InChIKey | CDPXLMFQNPLUBE-OAHLLOKOSA-N |
| XLogP | 2.94 |
| TPSA | 76.58 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 422.41 |
| LogP ≤ 5 | 2.94 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 175711335 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.